Q4 EPS Estimate for United Therapeutics Lowered by Analyst

United Therapeutics Co. (NASDAQ:UTHR) – Equities research analysts at Leerink Partnrs lowered their Q4 2024 EPS estimates for shares of United Therapeutics in a report released on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects that the biotechnology company will post earnings per share of $6.90 for the quarter, down from their prior forecast of $7.77. The consensus estimate for United Therapeutics’ current full-year earnings is $25.21 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q4 2025 earnings at $7.85 EPS.

Other analysts have also recently issued reports about the company. HC Wainwright increased their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH increased their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. UBS Group increased their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, The Goldman Sachs Group increased their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $382.08.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $370.44 on Thursday. The business has a 50 day simple moving average of $361.91 and a 200 day simple moving average of $358.41. United Therapeutics has a 52-week low of $211.61 and a 52-week high of $417.82. The stock has a market cap of $16.54 billion, a price-to-earnings ratio of 16.27, a PEG ratio of 0.92 and a beta of 0.57.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. This trade represents a 17.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the sale, the director now directly owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 121,864 shares of company stock valued at $44,516,965. 11.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. acquired a new stake in shares of United Therapeutics during the fourth quarter worth $25,000. Brooklyn Investment Group bought a new position in United Therapeutics in the third quarter valued at about $33,000. Millstone Evans Group LLC bought a new position in United Therapeutics in the fourth quarter valued at about $67,000. Capital Performance Advisors LLP bought a new position in United Therapeutics in the third quarter valued at about $82,000. Finally, MassMutual Private Wealth & Trust FSB grew its position in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.